Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dementia01:30

Dementia

476
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
476
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

731
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
731
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.5K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.5K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

1.6K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.6K
Levels of Health Promotion and Illness Prevention01:26

Levels of Health Promotion and Illness Prevention

14.1K
Health promotion allows a person to control the determinants of health, resulting in an improved health status. It enhances the quality of life and reduces premature deaths. Health promotion and illness prevention programs help people make beneficial choices to reduce the risk of disease and disabilities. There are three health promotion and illness prevention levels: primary, secondary, and tertiary prevention.
In primary prevention, actions taken before disease onset prevent the disease from...
14.1K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

916
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
916

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Co-expression-based models improve eQTL predictions for transcriptome-wide association studies and highlight new schizophrenia-associated genes.

Nature genetics·2026
Same author

Severe Hypertriglyceridemia Managed in a Pregnant Patient Using Nonstatin Therapies.

JACC. Case reports·2026
Same author

Negative symptoms in schizophrenia: Methodological challenges and emerging solutions for outcome measurement.

Neuroscience applied·2026
Same author

Xanomeline/trospium and suicide-related events in schizophrenia: An early pharmacovigilance analysis.

Schizophrenia research·2026
Same author

Moderate to severe negative symptoms predict low risk of symptoms worsening in schizophrenia patients in CATIE.

Schizophrenia research·2026
Same author

Modeling Negative Symptom Domain Neurobiology: Protocol for an Observational, Transdiagnostic, Translational Study.

JMIR research protocols·2026
Same journal

Mapping topological abnormalities in cortical similarity networks to schizophrenia-associated gene expression.

Dialogues in clinical neuroscience·2026
Same journal

Poor sleep quality correlates with axial symptoms and mood problems in Parkinson's disease.

Dialogues in clinical neuroscience·2026
Same journal

Treatment of posttraumatic stress disorder (PTSD).

Dialogues in clinical neuroscience·2026
Same journal

Comparisons of thalamocortical functional connectivity in transgender women and cisgender individuals: associations with cognition in a Chinese cohort.

Dialogues in clinical neuroscience·2026
Same journal

The Arabic Generalized Anxiety Disorder 2 (GAD-2): Psychometric evaluation among mothers of children with intellectual disabilities.

Dialogues in clinical neuroscience·2026
Same journal

Polarisation of brain dynamics in mania and depression.

Dialogues in clinical neuroscience·2026
See all related articles

Related Experiment Video

Updated: Jan 5, 2026

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

7.9K

Is dementia a preventable disease ?

Michael Davidson, Florence Thibaut1

  • 1University Hospital Cochin (site Tarnier), Faculty of Medicine Paris Descartes (University Sorbonne-Paris Cité), INSERM U 894, IPN, Paris, France.

Dialogues in Clinical Neuroscience
|October 15, 2019
PubMed
Summary
This summary is machine-generated.

Cognitive training, blood pressure management, and physical activity show moderate evidence for delaying Alzheimer's disease (AD) onset or progression. Other interventions are still under investigation or have yielded inconclusive results.

Area of Science:

  • Neurology
  • Gerontology
  • Preventive Medicine

Background:

  • Alzheimer's disease (AD) poses a significant public health challenge.

More Related Videos

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
06:23

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease

Published on: October 13, 2016

33.7K
Using Retinal Imaging to Study Dementia
09:17

Using Retinal Imaging to Study Dementia

Published on: November 6, 2017

22.1K

Related Experiment Videos

Last Updated: Jan 5, 2026

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

7.9K
The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
06:23

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease

Published on: October 13, 2016

33.7K
Using Retinal Imaging to Study Dementia
09:17

Using Retinal Imaging to Study Dementia

Published on: November 6, 2017

22.1K
  • Effective preventive strategies are crucial for managing AD's growing impact.
  • Current evidence for AD prevention is evolving, necessitating updated reviews.